The U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for V114, Merck’s investigational 15-valent pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in adults 18 years of age and older.
Merck announced the FDA set a Prescription Drug User Fee Act, or target action date, of July 18, 2021.
U.S. FDA Accepts for Priority Review the Biologics License Application for Investigational 15-valent Pneumococcal Vaccine
Composition of Gut Microbiome Altered in Patients With COVID-19
Several gut commensals with known immunomodulatory potential underrepresented in patients with COVID-19
Ischemic Heart, Hypertensive Disease Deaths Up During COVID-19
Second study shows reduction in cardiovascular diagnostic testing across the world during pandemic
Saliva, Nasopharyngeal Samples Equally Sensitive for SARS-CoV-2
Incremental cost of $8,093 per additional detection found with nasopharyngeal swab among individuals without previous SARS-CoV-2
Disneyland to Be Mass COVID-19 Vaccination Site
California’s Orange County plans to open more ‘Super Point-of-Dispensing’ sites soon